Renalytix AI PLC ADR (RNLX): Price and Financial Metrics
RNLX Price/Volume Stats
| Current price | $0.83 | 52-week high | $4.04 |
| Prev. close | $0.82 | 52-week low | $0.24 |
| Day low | $0.81 | Volume | 123,700 |
| Day high | $0.89 | Avg. volume | 1,674,605 |
| 50-day MA | $0.89 | Dividend yield | N/A |
| 200-day MA | $1.38 | Market Cap | 41.47M |
RNLX Stock Price Chart Interactive Chart >
Renalytix AI PLC ADR (RNLX) Company Bio
Renalytix AI Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded on March 15,2018 and is headquartered in Penarth, the United Kingdom.
Latest RNLX News From Around the Web
Below are the latest news stories about RENALYTIX PLC that investors may wish to consider to help them evaluate RNLX as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! |
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal first quarter ended September 30, 2023. Recent Highlights (including post period events) Financing discussions in process with goal to provide operating runway |
Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT). Conference Call Detail |
What Makes Renalytix AI PLC Sponsored ADR (RNLX) a New Strong Buy StockRenalytix AI PLC Sponsored ADR (RNLX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to RenalytixLONDON and SALT LAKE CITY, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood test to assess risk of progressive kidney function decline for individuals with type 2 diabetes and early-stage chronic kidney disease, announces that the US Patent Office has issued a new notice of allowance of claims surrounding the biomarkers sTNFR1 and sTNFR2 used in the kidneyintelX.dkd test. Th |
RNLX Price Returns
| 1-mo | -20.19% |
| 3-mo | 218.01% |
| 6-mo | -31.40% |
| 1-year | -65.98% |
| 3-year | -96.76% |
| 5-year | N/A |
| YTD | 112.82% |
| 2023 | -79.14% |
| 2022 | -88.24% |
| 2021 | -0.62% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...